Caris Life Sciences is a private precision-medicine and molecular diagnostics company focused on cancer care. It uses genomic, transcriptomic, proteomic, and AI-driven analysis to help physicians match patients to more personalized treatment options.
UpMarket does not offer Caris Life Sciences shares. This page covers Caris Life Sciences's history before it went public.
Caris Life Sciences became a public company on June 18, 2025 and trades on Nasdaq as CAI. UpMarket does not offer Caris Life Sciences shares. This page covers Caris Life Sciences's valuation and funding history before it went public.
Caris Life Sciences listed on Nasdaq under the ticker CAI on June 18, 2025.
See how Caris Life Sciences's private-market valuation changed across funding rounds before it went public.
See reported funding rounds and revenue figures on this page, with their sources.
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| 2025 | IPO |
Caris Life Sciences announced an $830 million growth equity round at a $7.83 billion post-money valuation in May 2021. The company said the financing brought total external funding since 2018 to about $1.3 billion and backed commercial expansion.
In its 2020 growth-capital announcement, Caris said it used AI on a 215,000-patient database with molecular and clinical outcome data. The company described its tumor profiling platform as market-leading, with broad actionable biomarker coverage and proprietary molecular signature analytics.
Caris said new capital would support a first-in-class liquid biopsy platform for therapy selection, recurrence monitoring, and early screening across cancer types. The company also said it would expand clinical trial delivery services and biopharmaceutical partnerships, widening its precision-medicine market.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
Browse the directory →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
Yes. Caris Life Sciences became a public company on June 18, 2025 and trades on Nasdaq under the ticker CAI. UpMarket does not offer Caris Life Sciences shares.
Caris Life Sciences's share price is set on the public market under the ticker CAI. The prices shown on this page are historical private-market prices from before it went public.
No. Caris Life Sciences is now a public company and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Caris Life Sciences is now publicly traded, so its shares can be bought and sold on Nasdaq and their price can change significantly. Review Caris Life Sciences's public filings and consult a financial advisor before investing. UpMarket does not offer Caris Life Sciences shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Caris Life Sciences became a public company on June 18, 2025, so shares held before the listing can generally be sold on the public market once any lock-up period ends. The exact terms depend on how the shares are held, for example directly or through a fund.
UpMarket does not offer Caris Life Sciences shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
Caris Life Sciences's valuation is now set by its public share price on Nasdaq. The figures on this page show its valuation history before it went public.
Caris Life Sciences generated $812.0M in 2025 revenue and uses genomic, transcriptomic, proteomic, and AI-driven analysis for cancer care, after raising $830M at a $7.83B valuation in 2021. Caris Life Sciences is now a public company, and UpMarket does not offer its shares.